GlassScriptPhysician profile
Kristen James
NPI 1770977100
$640.84
in general payments reported to CMS, 2019-2025
12 companies · $22.35 in 2025
The $22.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $163 · 2021: $62.11 · 2022: $97.15 · 2023: $20.87 · 2024: $17.71 · 2025: $22.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.23 | 2019-2022 | |
| Sage Therapeutics, LLC | $104.15 | 2020 | |
| Merck Sharp & Dohme LLC | $43.30 | 2020 | |
| Hologic Sales and Service, LLC | $34.60 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $29.14 | 2022-2023 | |
| Organon LLC | $28.25 | 2021-2022 | |
| Atricure, INC. | $22.35 | 2025 | Synergy Ablation System |
| Exeltis, USA INC. | $20.86 | 2022 | |
| Agile Therapeutics, INC. | $17.71 | 2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2021 | |
| Myovant Sciences INC. | $15.60 | 2021 | |
| Astellas Pharma US INC | $15.30 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.